Barclays
AGN.PRA

Barclays’s Allergan plc AGN.PRA Stock Holding History

Barclays’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,120
Closed -$2.42M – 7596
2017
Q4 		$2.42M Sell
4,120
-1,602
-28% -$1.03M ﹤0.01% 2268
2017
Q3 		$4.22M Buy
5,722
+4,038
+240% +$3.35M ﹤0.01% 1666
2017
Q2 		$1.46M Sell
1,684
-7,703
-82% -$6.45M ﹤0.01% 2537
2017
Q1 		$7.96M Sell
9,387
-2,443
-21% -$2.02M 0.01% 1027
2016
Q4 		$9.02M Sell
11,830
-23,853
-67% -$18M 0.01% 1005
2016
Q3 		$29.3M Buy
35,683
+8,453
+31% +$7.31M 0.03% 405
2016
Q2 		$22.7M Buy
27,230
+3,598
+15% +$3.01M 0.03% 477
2016
Q1 		$21.7M Buy
23,632
+18,625
+372% +$17.8M 0.03% 445
2015
Q4 		$5.15M Buy
5,007
+2,054
+70% +$2.06M 0.01% 1297
2015
Q3 		$2.79M Sell
2,953
-306
-9% -$319K ﹤0.01% 1839
2015
Q2 		$3.41M Buy
+3,259
New +$3.41M ﹤0.01% 1794

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

Barclays's AGN.PRA Position: Q1 2018 in Review

Barclays sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 4,120 shares — an estimated $2.42M sold.

Barclays first reported a position in AGN.PRA in Q2 2015 and held it in 11 quarters. The position peaked at $29.3M in Q3 2016. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • Barclays reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 4,120 Allergan plc shares in Q1 2018, an estimated $2.42M.
  • Barclays first reported a position in Allergan plc in Q2 2015 and held it in 11 quarters.
  • Barclays's Allergan plc position peaked at $29.3M in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.